Darnitsa Implementing the Production Development Strategy Until 203026 July 2021
Within the framework of implementation of the continuous improvement philosophy, Darnitsa Pharmaceutical Company proceeded to the second stage of implementation of projects aimed at improvement of production processes. As part of the implemented projects, the company achieved the average annual reduction of the time for equipment reconfiguration operations by 32.2%.
Dmytro Shymkiv, Chairman of the Board of Directors of Darnitsa Group: “When developing projects to improve production, we primarily focus on operations and processes that add value to the consumer. In 2020, we allocated UAH 180.5 million of capital investments for modernization of the production and ensuring its compliance with international standards, maintenance of high quality with minimal resource consumption, reduction of the production time. We paid special attention to the organization of supply and satisfaction of the demand for medicines regardless of environmental turbulence.”
Darnitsa’s production development strategy is designed until 2030 and in addition to consistent investments in modernization includes a philosophy of continuous improvement of processes and involvement of all employees for maximum focus on the interests and needs of consumers.
In particular, the company uses SMED (Single-Minute Exchange of Dies) tools to increase the efficiency of production processes. In 2020, 8 such projects were completed, with the average reduction in the operation time in the production units, where restructuring projects were implemented, amounting to 24.4%. During the 6 months of 2021, 5 projects were completed, which reduced the duration of reconfiguration by an average of 32.2%. Since the beginning of the SMED program, the total execution time of reconfiguration operations in the company has been reduced by 1.7%.
Also in 2020, a large-scale training on the implementation of Kaizen projects was performed; the implementation of projects aimed at improving the quality management process, increasing operational efficiency and saving resources is coming to an end.
Darnitsa is the largest EU GMP-certified drug manufacturer in Ukraine. During 2010-2020, the company invested UAH 1.218 billion in modernization and development of the production. Due to the focus on the development and use of innovative technologies and equipment, Darnitsa ensures that the production of medicines takes place under controlled conditions in compliance with GMP requirements. The company's mission is to help healthcare professionals and patients to improve their quality of life through science, innovation and accessibility for all.
The beneficiaries of the company are the Zagoriy family.